Core Viewpoint - X4 Pharmaceuticals has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use recommending the marketing authorization of mavorixafor for treating WHIM syndrome in the EU, marking a significant step towards providing the first therapy for this ultra-rare immune disorder [1][2]. Company Overview - X4 Pharmaceuticals focuses on developing therapies for rare hematology diseases, with mavorixafor being a key product aimed at addressing significant unmet medical needs in patients with WHIM syndrome [2][13]. - The company has entered a licensing and supply agreement with Norgine for the commercialization of mavorixafor in Europe, Australia, and New Zealand, which includes potential milestone payments of up to €226 million and royalties on future sales [5]. Product Information - Mavorixafor, marketed as XOLREMDI in the U.S., is an oral therapy approved for patients aged 12 and older with WHIM syndrome, designed to increase circulating mature neutrophils and lymphocytes [3]. - The drug's efficacy was demonstrated in a Phase 3 clinical trial (4WHIM), showing significant improvements in absolute neutrophil and lymphocyte counts, as well as a 60% reduction in the annualized infection rate compared to placebo [4]. Clinical Trial Results - The pivotal 4WHIM trial involved 31 participants and showed a statistically significant increase in time above threshold for absolute neutrophil count and absolute lymphocyte count compared to placebo (p<0.0001) [4]. - The trial also indicated an approximate 40% reduction in total infection scores for patients treated with XOLREMDI compared to those receiving placebo [4]. Market Potential - The positive opinion from the CHMP is expected to facilitate patient access to mavorixafor, potentially making it the first and only therapy available in Europe for WHIM syndrome, which is characterized by severe immunodeficiency and frequent infections [2][12].